# A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

> **NCT04576156** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Geron Corporation** · enrollment: 327 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Imetelstat
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT04576156
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-12
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04576156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04576156, "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04576156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*